Ann: Annual Report to shareholders, page-2

As per excerpt below, this is the big one with the 2nd largest global market, or effectively largest market pre Covid-19 and provides the biggest opportunity for new customers with its ability to test for numerous STD’s. With Europe also experiencing a significant 2nd wave of coronavirus, both sectors provide for ongoing substantial revenue growth.
“Genetic Signatures has determined that STIs are a significant market opportunity and has completed development and validation of a detection kit and submitted applications for regulatory approvals in both Europe (CE-IVD) and Australia (TGA) this year.These registrations are expected before the endof 2020. The Company’s EasyScreenTM STI/Genital Pathogen Detection Kit simultaneously detects 12 of the most commonly encountered STIs.Sexually Transmitted Infections (STI’s) can havea significant impact on sexual and reproductive health. There are an estimated 1 million STI’s contracted daily around the world, and the 4most commonly reported infections (Chlamydia, Gonorrhoea, Syphilis and Trichomoniasis) account for approximately 376 million cases per annum13. The testing market value is estimated to be US$420m pa just for Chlamydia and Gonorrhoea14, and forecast to grow at 7% p.a.”